1
|
Wada Y, Kondo M, Sakairi K, Nagashima A, Tokita K, Tominaga H, Tomiyama H, Ishikawa T. Renoprotective Effects of a Novel Receptor-Interacting Protein Kinase 2 Inhibitor, AS3334034, in Uninephrectomized Adriamycin-Induced Chronic Kidney Disease Rats. J Pharmacol Exp Ther 2020; 374:428-437. [PMID: 32561685 DOI: 10.1124/jpet.120.265678] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Accepted: 06/12/2020] [Indexed: 12/16/2022] Open
Abstract
Renal inflammation is a final common pathway of chronic kidney disease (CKD), and its progression can be used to effectively gauge the degree of renal dysfunction. Inflammatory mechanisms contribute to glomerulosclerosis and tubulointerstitial fibrosis, which are hallmarks of CKD leading to end-stage renal disease. Receptor-interacting protein kinase 2 (RIP2) is largely committed to nucleotide-binding oligomerization domain signaling as a direct effector and transmits nuclear factor-κB (NF-κB)-mediated proinflammatory cytokine production. In the present study, we hypothesized that if inflammation via RIP2 and NF-κB signaling plays an important role in renal failure, then the anti-inflammatory effect of RIP2 inhibitors should be effective in improving CKD. To determine its pharmacologic potency, we investigated the renoprotective properties of the novel RIP2 inhibitor AS3334034 [7-methoxy-6-(2-methylpropane-2-sulfonyl)-N-(4-methyl-1H-pyrazol-3-yl)quinolin-4-amine] in uninephrectomized adriamycin-induced CKD rats. Six weeks' repeated administration of AS3334034 (10 mg/kg, once daily) significantly reduced urinary protein excretion and prevented the development of glomerulosclerosis and tubulointerstitial fibrosis. In addition, AS3334034 showed beneficial effects on renal function, as demonstrated by a decrease in levels of plasma creatinine and blood urea nitrogen and attenuation of a decline in creatinine clearance. Furthermore, AS3334034 significantly attenuated inflammation, renal apoptosis, and glomerular podocyte loss. These results suggest that the RIP2 inhibitor AS3334034 suppresses the progression of chronic renal failure via an anti-inflammatory effect and is therefore potentially useful in treating patients with CKD. SIGNIFICANCE STATEMENT: The receptor-interacting protein kinase 2 (RIP2) inhibitor AS3334034 suppresses the progression of chronic renal failure via an anti-inflammatory effect, suggesting that the nucleotide-binding oligomerization domain-RIP2 axis might play a crucial role in the pathogenesis of inflammatory kidney diseases. AS3334034 is expected to be potentially useful in the treatment of patients with chronic kidney disease.
Collapse
Affiliation(s)
- Yusuke Wada
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan (Y.W., M.K., K.S., A.N., K.T., H.T.); Research and Development Department, Kotobuki Pharmaceutical Co., Ltd., Nagano, Japan (H.T.); and Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (Y.W., T.I.)
| | - Mitsuhiro Kondo
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan (Y.W., M.K., K.S., A.N., K.T., H.T.); Research and Development Department, Kotobuki Pharmaceutical Co., Ltd., Nagano, Japan (H.T.); and Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (Y.W., T.I.)
| | - Kumi Sakairi
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan (Y.W., M.K., K.S., A.N., K.T., H.T.); Research and Development Department, Kotobuki Pharmaceutical Co., Ltd., Nagano, Japan (H.T.); and Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (Y.W., T.I.)
| | - Akira Nagashima
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan (Y.W., M.K., K.S., A.N., K.T., H.T.); Research and Development Department, Kotobuki Pharmaceutical Co., Ltd., Nagano, Japan (H.T.); and Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (Y.W., T.I.)
| | - Kenichi Tokita
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan (Y.W., M.K., K.S., A.N., K.T., H.T.); Research and Development Department, Kotobuki Pharmaceutical Co., Ltd., Nagano, Japan (H.T.); and Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (Y.W., T.I.)
| | - Hiroaki Tominaga
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan (Y.W., M.K., K.S., A.N., K.T., H.T.); Research and Development Department, Kotobuki Pharmaceutical Co., Ltd., Nagano, Japan (H.T.); and Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (Y.W., T.I.)
| | - Hiroshi Tomiyama
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan (Y.W., M.K., K.S., A.N., K.T., H.T.); Research and Development Department, Kotobuki Pharmaceutical Co., Ltd., Nagano, Japan (H.T.); and Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (Y.W., T.I.)
| | - Tomohisa Ishikawa
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan (Y.W., M.K., K.S., A.N., K.T., H.T.); Research and Development Department, Kotobuki Pharmaceutical Co., Ltd., Nagano, Japan (H.T.); and Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (Y.W., T.I.)
| |
Collapse
|
2
|
Satia I, Nagashima A, Usmani OS. Exploring the role of nerves in asthma; insights from the study of cough. Biochem Pharmacol 2020; 179:113901. [PMID: 32156662 DOI: 10.1016/j.bcp.2020.113901] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2020] [Accepted: 03/03/2020] [Indexed: 12/30/2022]
Abstract
Cough in asthma predicts disease severity, prognosis, and is a common and troublesome symptom. Cough is the archetypal airway neuronal reflex, yet little is understood about the underlying neuronal mechanisms. It is generally assumed that symptoms arise because of airway hyper-responsiveness and/or airway inflammation, but despite using inhaled corticosteroids and bronchodilators targeting these pathologies, a large proportion of patients have persistent coughing. This review focuses on the prevalence and impact of cough in asthma and explores data from pre-clinical and clinical studies which have explored neuronal mechanisms of cough and asthma. We present evidence to suggest patients with asthma have evidence of neuronal dysfunction, which is further heightened and exaggerated by both bronchoconstriction and airway eosinophilia. Identifying patients with excessive coughing with asthma may represent a neuro-phenotype and hence developing treatment for this symptom is important for reducing the burden of disease on patients' lives and currently represents a major unmet clinical need.
Collapse
Affiliation(s)
- I Satia
- McMaster University, Department of Medicine, Division of Respirology, Canada; Firestone Institute for Respiratory Health, St Joseph's Hospital, Canada; University of Manchester, Division of Infection, Immunity and Respiratory Medicine, and Manchester Academic Health Science Centre, Manchester, United Kingdom.
| | - A Nagashima
- McMaster University, Department of Medicine, Division of Respirology, Canada
| | | |
Collapse
|
3
|
Nakashima T, Nonoshita T, Hirata H, Inoue K, Nagashima A, Yoshitake T, Asai K, Shioyama Y. Adverse Events of Concurrent Radiotherapy and ALK Inhibitors for Brain Metastases of ALK-Rearranged Lung Adenocarcinoma. In Vivo 2020; 34:247-253. [PMID: 31882485 PMCID: PMC6984098 DOI: 10.21873/invivo.11767] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2019] [Revised: 10/04/2019] [Accepted: 10/11/2019] [Indexed: 12/22/2022]
Abstract
BACKGROUND We investigated acute adverse events in patients with brain metastases (BMs) of anaplastic lymphoma kinase-rearranged (ALKr) non-small cell lung cancer (NSCLC) treated with both cranial radiotherapy and tyrosine kinase inhibitors (TKIs) of ALK. PATIENTS AND METHODS Acute AEs were retrospectively investigated in patients with BMs of ALKr-NSCLC who received both whole-brain radiotherapy (WBRT) and ALK-TKI. For comparison, they were also assessed in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC and wild-type with neither ALK rearrangement nor EGFR mutation treated with WBRT. RESULTS Two ALKr cases were consequently eligible. Grade 3 otitis media unexpectedly occurred in both cases, while there was one case out of 11 and one case out of 18 of grade 2 otitis media among the EGFR-mutated cases and wild-type cases (p=0.013), respectively. CONCLUSION Concurrent treatment with WBRT and ALK-TKI may be associated with acute severe ear toxicity in patients with BMs of ALKr-NSCLC.
Collapse
Affiliation(s)
- Takaaki Nakashima
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
- Department of Radiology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| | - Takeshi Nonoshita
- Department of Radiology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| | - Hidenari Hirata
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Kouji Inoue
- Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| | - Akira Nagashima
- Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| | - Tadamasa Yoshitake
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Kaori Asai
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Yoshiyuki Shioyama
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| |
Collapse
|
4
|
Ohgushi A, Nakayama N, Namiki A, Nagashima A, Ogawa R, Akazawa M, Echizen H. A Retrospective Evaluation of the Impact of Multi-disciplinary Approach for Improving the Quality of Anticoagulation Therapy in Ambulatory Patients with Non-valvular Atrial Fibrillation Receiving Warfarin. YAKUGAKU ZASSHI 2019; 139:1177-1183. [DOI: 10.1248/yakushi.18-00209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Atsushi Ohgushi
- Department of Hospital Pharmacy, Japan Organization of Occupational Health and Safety, Kanto Rosai Hospital
| | - Natsumi Nakayama
- Department of Hospital Pharmacy, Japan Organization of Occupational Health and Safety, Kanto Rosai Hospital
| | - Atsuo Namiki
- Department of Cardiology, Japan Organization of Occupational Health and Safety, Kanto Rosai Hospital
| | - Akira Nagashima
- Department of Hospital Pharmacy, Japan Organization of Occupational Health and Safety, Spinal Injuries Center
| | - Ryuichi Ogawa
- Department of Pharmacotherapy, Meiji Pharmaceutical University
| | - Manabu Akazawa
- Department of Public Health and Epidemiology, Meiji Pharmaceutical University
| | | |
Collapse
|
5
|
Okamoto T, Yano T, Shimokawa M, Takeo S, Yamazaki K, Sugio K, Takenoyama M, Nagashima A, Tsukamoto S, Hamatake M, Yokoyama H, Ueda H, Motohiro A, Tagawa T, Shoji F, Kometani T, Saito G, Fukuyama Y, Toyokawa G, Osoegawa A, Emi Y, Maehara Y. A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer. Lung Cancer 2018; 124:255-259. [PMID: 30268470 DOI: 10.1016/j.lungcan.2018.08.015] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2018] [Revised: 07/03/2018] [Accepted: 08/17/2018] [Indexed: 12/25/2022]
Abstract
OBJECTIVES Platinum-based combination chemotherapy is the standard postoperative adjuvant treatment for pathological stage II/III non-small cell lung cancer (NSCLC). Oral S-1 therapy has good efficacy and relatively low toxicity for the treatment of advanced NSCLC. We investigated whether long-term S-1 monotherapy is also useful as an adjuvant therapy after surgery in patients with NSCLC. PATIENTS AND METHODS We conducted a phase II randomized open-label multi-institutional study in patients with pathological stage II/IIIA NSCLC (7th TNM classification) who underwent complete resection from 2009 to 2013. The primary endpoint, the 2-year disease-free survival (DFS) rate, was evaluated using the Bayesian method. Eligible patients were randomly assigned to two arms: oral S-1 monotherapy (S-1 arm) and S-1 plus cisplatin combination therapy followed by S-1 (S-1 plus cisplatin arm) both for a total of 1 year. RESULTS A total of 70 and 71 patients were enrolled in S-1 arm and S-1 plus cisplatin arm, respectively. The 2-year DFS rates were 52% (95% confidence interval [CI], 0.40-0.63) and 61% (95% CI, 0.48-0.70) for S-1 arm and S-1 plus cisplatin arm, respectively. Both arms met the primary endpoint. Neither DFS nor OS was significantly different between the arms (log-rank test: P = 0.1695 and P = 0.8684, respectively). The main G3/4 adverse events were loss of appetite and anemia (S-1 vs. S-1 plus cisplatin: 4.3% vs. 11.6% and 0% vs. 5.8%, respectively). The treatment completion rate did not differ between the two arms (S-1 vs. S-1 plus cisplatin: 45.7%, 95% CI, 41.9-66.3% vs. 43.5% 95% CI, 44.0-68.4%). CONCLUSIONS Long-term adjuvant chemotherapy with S-1 was a feasible and promising treatment for patients with completely resected NSCLC, regardless of cisplatin addition. S-1 monotherapy should be investigated further, based on its low toxicity and practical convenience.
Collapse
Affiliation(s)
- Tatsuro Okamoto
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan.
| | - Tokujiro Yano
- Department of General Thoracic Surgery, National Hospital Organization Beppu Medical Center, Beppu, Japan
| | | | - Sadanori Takeo
- Department of Thoracic Surgery and Clinical Research Institute, National Hospital Organization Kyushu Medical Center Hospital, Fukuoka, Japan
| | - Koji Yamazaki
- Department of Thoracic Surgery and Clinical Research Institute, National Hospital Organization Kyushu Medical Center Hospital, Fukuoka, Japan; Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan
| | - Kenji Sugio
- Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan; Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | | | - Akira Nagashima
- Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| | - Shuichi Tsukamoto
- Department of Thoracic Surgery, Steel Memorial Yawata Hospital, Kitakyushu, Japan
| | - Motoharu Hamatake
- Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Department of Surgery, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, Japan
| | - Hideki Yokoyama
- Department of Thoracic Surgery, Matsuyama Red Cross Hospital, Matsuyama, Japan
| | - Hitoshi Ueda
- Department of Surgery, National Hospital Organization Fukuoka Hospital, Fukuoka, Japan
| | - Akira Motohiro
- Department of Thoracic Surgery, Oita Red Cross Hospital, Oita, Japan
| | - Tetsuzo Tagawa
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Thoracic Surgery, Oita Red Cross Hospital, Oita, Japan
| | - Fumihiro Shoji
- Department of Thoracic Surgery, Oita Red Cross Hospital, Oita, Japan; Department of Thoracic Surgery, Kyushu Center Hospital, Fukuoka, Japan
| | - Takuro Kometani
- Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan; Department of Thoracic Surgery, National Hospital Organization Oita Medical Center, Oita, Japan
| | - Genkichi Saito
- Department of Thoracic Surgery, Kyushu Center Hospital, Fukuoka, Japan
| | - Yasuro Fukuyama
- Department of Thoracic Surgery, Nakatsu Municipal Hospital, Nakatsu, Japan
| | - Gouji Toyokawa
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Atsushi Osoegawa
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan
| | - Yasunori Emi
- Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan
| | - Yoshihiko Maehara
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| |
Collapse
|
6
|
Sato H, Abe H, Nagashima A, Yokoyama J, Terai S. Gastrointestinal: A rare case of concomitant type III achalasia and chronic idiopathic intestinal pseudo-obstruction. J Gastroenterol Hepatol 2018; 33:559. [PMID: 29469232 DOI: 10.1111/jgh.13980] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Affiliation(s)
- H Sato
- Division of Gastroenterology and Hepatology, Niigata University Medical and Dental Hospital, Niigata, Japan
| | - H Abe
- Division of Gastroenterology and Hepatology, Niigata University Medical and Dental Hospital, Niigata, Japan
| | - A Nagashima
- Division of Gastroenterology and Hepatology, Niigata University Medical and Dental Hospital, Niigata, Japan
| | - J Yokoyama
- Division of Gastroenterology and Hepatology, Niigata University Medical and Dental Hospital, Niigata, Japan
| | - S Terai
- Division of Gastroenterology and Hepatology, Niigata University Medical and Dental Hospital, Niigata, Japan
| |
Collapse
|
7
|
Yamaki S, Yamada H, Nagashima A, Kondo M, Shimada Y, Kadono K, Yoshihara K. Synthesis and structure activity relationships of carbamimidoylcarbamate derivatives as novel vascular adhesion protein-1 inhibitors. Bioorg Med Chem 2017; 25:6024-6038. [DOI: 10.1016/j.bmc.2017.09.036] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Revised: 09/21/2017] [Accepted: 09/22/2017] [Indexed: 12/22/2022]
|
8
|
Okamoto T, Yano T, Shimokawa M, Takeo S, Yamazaki K, Sugio K, Takenoyama M, Nagashima A, Tagawa T, Emi Y, Maehara Y. A phase II randomized trial of adjuvant chemotherapy for the patients completely resected pathological stage IB (T > 5cm), II, IIIA non-small cell lung cancer comparing S-1 versus S-1 with cisplatin. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx381.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
9
|
Yamaki S, Koga Y, Nagashima A, Kondo M, Shimada Y, Kadono K, Moritomo A, Yoshihara K. Synthesis and pharmacological evaluation of glycine amide derivatives as novel vascular adhesion protein-1 inhibitors without CYP3A4 and CYP2C19 inhibition. Bioorg Med Chem 2017; 25:4110-4122. [PMID: 28601507 DOI: 10.1016/j.bmc.2017.05.059] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2017] [Revised: 05/08/2017] [Accepted: 05/30/2017] [Indexed: 12/22/2022]
Abstract
Vascular adhesion protein-1 (VAP-1) is a promising therapeutic target for the treatment of diabetic nephropathy. Here, we conducted optimization studies of our lead compound 1, which we previously reported as a novel VAP-1 inhibitor, to enhance the inhibition of human VAP-1 and to reduce CYP3A4 and CYP2C19 inhibition. As a result, we identified 3-chloro-4-{4-[5-(3-{[glycyl(methyl)amino]methyl}phenyl)pyrimidin-2-yl]piperazin-1-yl}benzoic acid (17h) as a novel orally active VAP-1 inhibitor, with 14-fold increased human VAP-1 inhibitory activity compared to 1, without CYP3A4 and CYP2C19 inhibition. Oral administration of 17h significantly inhibited the progression of proteinuria in streptozotocin (STZ) induced diabetic rats at 0.3 and 1mg/kg, suggesting that this compound has potential to be a therapeutic agent for the treatment of diabetic nephropathy.
Collapse
Affiliation(s)
- Susumu Yamaki
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan.
| | - Yuji Koga
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Akira Nagashima
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Mitsuhiro Kondo
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Yoshiaki Shimada
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Keitaro Kadono
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Ayako Moritomo
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Kosei Yoshihara
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| |
Collapse
|
10
|
Fukuda T, Oikawa T, Takeji S, Isayama A, Kawano Y, Neyatani Y, Nagashima A, Nishitani T, Konoshima S, Tamai H, Fujita T, Sakamoto Y, Kamada Y, Ide S, Koide Y, Takenaga H, Kurihara K, Sakata S, Ozeki T, Kawamata Y, Miura YM. Advanced Real-Time Feedback Control in JT-60U High Performance Discharges for Application to Fusion Reactor Plasmas. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a233] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Fukuda
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - T. Oikawa
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - S. Takeji
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - A. Isayama
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Kawano
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Neyatani
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - A. Nagashima
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - T. Nishitani
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - S. Konoshima
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - H. Tamai
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - T. Fujita
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Sakamoto
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Kamada
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - S. Ide
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Koide
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - H. Takenaga
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - K. Kurihara
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - S. Sakata
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - T. Ozeki
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Kawamata
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. M. Miura
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| |
Collapse
|
11
|
Sugie T, Hatae T, Koide Y, Fujita T, Kusama Y, Nishitani T, Isayama A, Sato M, Shinohara K, Asakura N, Konoshima S, Kubo H, Takenaga H, Kawano Y, Kondoh T, Nagashima A, Fukuda T, Sunaoshi H, Naito O, Kitamura S, Tsukahara Y, Sakasai A, Sakamoto Y, Suzuki T, Tobita K, Nemoto M, Morioka A, Ishikawa M, Ishida S, Isei N, Oyama N, Neyatani Y, Itami K, Sakurai S, Tamai H, Tsuchiya K, Higashijima S, Nakano T, Nagaya S, Chiba S, Lee S, Shitomi M. Diagnostics System of JT-60U. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a242] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Sugie
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - T. Hatae
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - Y. Koide
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - T. Fujita
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - Y. Kusama
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - T. Nishitani
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - A. Isayama
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - M. Sato
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - K. Shinohara
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - N. Asakura
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - S. Konoshima
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - H. Kubo
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - H. Takenaga
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - Y. Kawano
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - T. Kondoh
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - A. Nagashima
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - T. Fukuda
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - H. Sunaoshi
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - O. Naito
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - S. Kitamura
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - Y. Tsukahara
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - A. Sakasai
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - Y. Sakamoto
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - T. Suzuki
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - K. Tobita
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - M. Nemoto
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - A. Morioka
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - M. Ishikawa
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - S. Ishida
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - N. Isei
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - N. Oyama
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - Y. Neyatani
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - K. Itami
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - S. Sakurai
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - H. Tamai
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - K. Tsuchiya
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - S. Higashijima
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - T. Nakano
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - S. Nagaya
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - S. Chiba
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - S. Lee
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - M. Shitomi
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-01 Mukoyama, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| |
Collapse
|
12
|
Yamaki S, Suzuki D, Fujiyasu J, Neya M, Nagashima A, Kondo M, Akabane T, Kadono K, Moritomo A, Yoshihara K. Synthesis and structure activity relationships of glycine amide derivatives as novel Vascular Adhesion Protein-1 inhibitors. Bioorg Med Chem 2016; 25:187-201. [PMID: 27810440 DOI: 10.1016/j.bmc.2016.10.025] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2016] [Revised: 10/18/2016] [Accepted: 10/19/2016] [Indexed: 12/14/2022]
Abstract
Vascular Adhesion Protein-1 (VAP-1) is a promising therapeutic target for the treatment of several inflammatory-related diseases including diabetic microvascular complication. We identified glycine amide derivative 3 as a novel structure with moderate VAP-1 inhibitory activity. Structure-activity relationship studies of glycine amide derivatives revealed that the tertiary amide moiety is important for stability in rat blood and that the position of substituents on the left phenyl ring plays an important role in VAP-1 inhibitory activity. We also found that low TPSA values and weak basicity are both important for high PAMPA values for glycine amide derivatives. These findings led to the identification of a series of orally active compounds with enhanced VAP-1 inhibitory activity. Of these compounds, 4g exhibited the most potent ex vivo efficacy, with plasma VAP-1 inhibitory activity of 60% after oral administration at 1mg/kg.
Collapse
Affiliation(s)
- Susumu Yamaki
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan.
| | - Daisuke Suzuki
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Jiro Fujiyasu
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Masahiro Neya
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Akira Nagashima
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Mitsuhiro Kondo
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Takafumi Akabane
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Keitaro Kadono
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Ayako Moritomo
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Kosei Yoshihara
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| |
Collapse
|
13
|
Haro A, Tamiya S, Nagashima A. A rare case of human pulmonary dirofilariasis with a growing pulmonary nodule after migrating infiltration shadows, mimicking primary lung carcinoma. Int J Surg Case Rep 2016; 22:8-11. [PMID: 27015012 PMCID: PMC4844670 DOI: 10.1016/j.ijscr.2016.03.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Revised: 03/15/2016] [Accepted: 03/15/2016] [Indexed: 12/20/2022] Open
Abstract
INTRODUCTION Pulmonary dirofilariasis is a rare pulmonary parasitic infection by the nematode Dirofilaria immitis. It is characterized by an asymptomatic pulmonary nodule usually seen on chest X-ray. The differential diagnosis of pulmonary dirofilariasis includes other pulmonary diseases, primary lung carcinoma and metastatic lung tumor. CASE PRESENTATION Pulmonary dirofilariasis was diagnosed in a woman who presented with interstitial pneumonia. Growth of the pulmonary nodule was detected subsequent to hemoptysis. The histological diagnosis was made based on a wedge resection performed under video-associated thoracic surgery (VATS). CONCLUSION Pulmonary dirofilariasis often varies in its clinical course. The diagnosis is best made using wedge resection under VATS.
Collapse
Affiliation(s)
- Akira Haro
- Department of Thoracic Surgery, Nakatsu Municipal Hospital, Japan; Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Japan.
| | - Sadafumi Tamiya
- Department of Diagnostic Pathology, Kitakyushu Municipal Medical Center, Japan
| | - Akira Nagashima
- Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Japan
| |
Collapse
|
14
|
Haro A, Nagashima A. A rare case report of rib hemangioma mimicking a malignant bone tumor or metastatic tumor. Int J Surg Case Rep 2015; 16:141-5. [PMID: 26454500 PMCID: PMC4643469 DOI: 10.1016/j.ijscr.2015.09.036] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Revised: 09/04/2015] [Accepted: 09/24/2015] [Indexed: 11/20/2022] Open
Abstract
Hemangioma of the rib is a rare benign vascular tumor. The chest computed tomography or magnetic resonance imaging of this disease often reveals malignant findings. Hemangioma of the rib should be considered in the differential diagnosis of malignant bone tumor.
Hemangioma of the rib is a rare benign vascular tumor. This benign disease induces osteolytic changes, and must be distinguished from a malignant bone tumor or metastatic tumor. Definitive diagnosis is achieved by excision biopsy or histological examination after surgical resection in many cases. We here in present a rare case of hemangioma of the rib.
Collapse
Affiliation(s)
- Akira Haro
- Department of Thoracic Surgery, Nakatsu Municipal Hospital, Japan; Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Japan.
| | - Akira Nagashima
- Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Japan
| |
Collapse
|
15
|
Haro A, Saitoh G, Tamiya S, Nagashima A. Four-year natural clinical course of pulmonary epithelioid hemangioendothelioma without therapy. Thorac Cancer 2015; 6:544-7. [PMID: 26273413 PMCID: PMC4511336 DOI: 10.1111/1759-7714.12192] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2014] [Accepted: 10/13/2014] [Indexed: 12/13/2022] Open
Abstract
Pulmonary epithelial hemangioendothelioma is a rare low to intermediate malignant vascular tumor originating from vascular endothelial cells. The therapy for this disease, if possible, is surgical resection. However, there is no standard treatment for patients with multiple unresectable lesions. We present the case of a 42-year-old woman treated with a natural clinical course of hemangioendothelioma for four years without therapy. The nodules have increased in number and size extremely slowly, and the patient is alive and asymptomatic four years after diagnosis.
Collapse
Affiliation(s)
- Akira Haro
- Department of Thoracic Surgery, Kitakyushu Municipal Medical Center Kokurakitaku, Fukuoka, Japan
| | - Genkichi Saitoh
- Department of Thoracic Surgery, Kitakyushu Municipal Medical Center Kokurakitaku, Fukuoka, Japan
| | - Sadafumi Tamiya
- Department of Diagnostic Pathology, Kitakyushu Municipal Medical Center Kokurakitaku, Fukuoka, Japan
| | - Akira Nagashima
- Department of Thoracic Surgery, Kitakyushu Municipal Medical Center Kokurakitaku, Fukuoka, Japan
| |
Collapse
|
16
|
Yasuda M, Nagashima A, Haro A, Saitoh G. How Should Synchronous Multiple Primary Adenocarcinomas of the Lung Be Resected? Ann Thorac Surg 2014; 97:e151-3. [DOI: 10.1016/j.athoracsur.2014.02.057] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2013] [Revised: 01/10/2014] [Accepted: 02/04/2014] [Indexed: 11/28/2022]
|
17
|
Ichiki Y, Nagashima A, Yasuda M, Takenoyama M, Toyoshima S. Surgical treatment of catamenial pneumothorax: Report of three cases. Asian J Surg 2013; 38:180-5. [PMID: 24210539 DOI: 10.1016/j.asjsur.2013.09.014] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2012] [Revised: 03/25/2013] [Accepted: 09/30/2013] [Indexed: 11/27/2022] Open
Abstract
Catamenial pneumothorax (CP) is a rare entity of spontaneous, recurring pneumothorax in females. Although it has been known to be associated with thoracic endometriosis, varying clinical course and the lack of consistent intraoperative findings have led to conflicting etiological theories. We herein discuss the etiology, clinical course, and surgical treatment of three patients with CP. Three females (aged 40 years, 28 years, and 34 years) had recurrent right-sided spontaneous pneumothoraces that coincided with their menses. They had undergone video-assisted thoracoscopic surgery (VATS) previously. Blueberry spots in the right diaphragm were detected in all three cases. Two patients had recurrence, postoperatively. The other patient, who received luteinizing hormone-releasing hormone analog therapy for an abdominal endometriosis in the perioperative period and postoperative chemical pleurodesis to prevent recurrence, has been free of recurrence for 15 months, postoperatively. However, pelvic endometriosis was detected in this patient only. Therefore, CP should be suspected in ovulating females with spontaneous pneumothorax, even in the absence of any symptoms associated with pelvic endometriosis. In addition, while performing VATS, careful inspection of the diaphragmatic surface is important. In complicated cases, hormonal suppression therapy and chemical pleurodesis might also be helpful adjunct modalities.
Collapse
Affiliation(s)
- Yoshinobu Ichiki
- Department of Chest Surgery and Pathology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
| | - Akira Nagashima
- Department of Chest Surgery and Pathology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| | - Manabu Yasuda
- Department of Chest Surgery and Pathology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| | - Mitsuhiro Takenoyama
- Department of Chest Surgery and Pathology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| | - Satoshi Toyoshima
- Department of Chest Surgery and Pathology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| |
Collapse
|
18
|
Ishikawa T, Kubota T, Hirose K, Abe H, Nagashima A, Seki K, Honma T, Yoshida T, Ishihara N. BTR May Be Useful Markers for Aggressive Therapy for Primary Hepatic Neuroendocrine Case with Jaundice. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt460.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Yasuda M, Nagashima A, Haro A, Saitoh G. Treatment of the postoperative recurrence of lung cancer in octogenarians. Surg Today 2013; 44:1626-32. [PMID: 24026198 DOI: 10.1007/s00595-013-0719-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2013] [Accepted: 07/24/2013] [Indexed: 12/26/2022]
Abstract
PURPOSE Guidelines for the treatment of postoperative recurrent lung cancer in octogenarians do not exist. In this study, we investigated the prognosis of patients with recurrence after the resection of lung cancer and discuss the management of recurrent tumors in octogenarians. METHODS This study clinicopathologically evaluated 135 octogenarians who underwent resections for lung cancer at a single institution between 1992 and 2010. We retrospectively reviewed the clinical records of 37 patients with confirmed recurrence. The overall survival of the patients and the treatments used for postoperative recurrence were evaluated. RESULTS Among 37 patients, six underwent intensive treatment, 14 underwent palliative treatment and 17 received supportive care only. The overall survival rates of the patients in the antitumor treatment groups tended to be associated with a better prognoses than those of the patients in the supportive care only group, but they did not exhibit significantly better prognoses at 1 year (p = 0.202). However, among the patients with a good performance status, the intensive treatment group tended to exhibit prolonged survival. Of the 37 patients with recurrent tumors, five (14%) died of other diseases. CONCLUSIONS Antitumor treatment of postoperative recurrent lung cancer in octogenarians may not always improve the survival rate. However, carefully selecting patients for intensive therapy, such as those with a good performance status, may lead to longer survival rates after postoperative recurrence in octogenarians.
Collapse
Affiliation(s)
- Manabu Yasuda
- Department of Chest Surgery, Kitakyushu Municipal Medical Center, 2-1-1 Basyaku, Kokurakita-ku, Kitakyushu, 802-0077, Japan,
| | | | | | | |
Collapse
|
20
|
Ichiki Y, Nagashima A, Yasuda M, Takenoyama M. Carcinoid tumors of the lung: A report of 11 cases. Asian J Surg 2013; 36:116-20. [DOI: 10.1016/j.asjsur.2012.11.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2012] [Revised: 04/30/2012] [Accepted: 10/31/2012] [Indexed: 10/27/2022] Open
|
21
|
Inoue T, Morita M, Tojo T, Nagashima A, Moritomo A, Miyake H. Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment. Bioorg Med Chem 2013; 21:3873-81. [PMID: 23664164 DOI: 10.1016/j.bmc.2013.04.011] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2013] [Revised: 04/02/2013] [Accepted: 04/04/2013] [Indexed: 10/26/2022]
Abstract
Novel thiazole derivatives were synthesized and evaluated as vascular adhesion protein-1 (VAP-1) inhibitors. Although we previously identified a compound (2) with potent VAP-1 inhibitory activity in rats, the human activity was relatively weak. Here, to improve the human VAP-1 inhibitory activity of compound 2, we first evaluated the structure-activity relationships of guanidine bioisosteres as simple small molecules and identified a 1H-benzimidazol-2-amine (5) with potent activity compared to phenylguanidine (1). Based on the structure of compound 5, we synthesized a highly potent VAP-1 inhibitor (37b; human IC50=0.019 μM, rat IC50=0.0051 μM). Orally administered compound 37b also markedly inhibited ocular permeability in streptozotocin-induced diabetic rats after oral administration, suggesting it is a promising compound for the treatment of diabetic macular edema.
Collapse
Affiliation(s)
- Takayuki Inoue
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan.
| | | | | | | | | | | |
Collapse
|
22
|
Yasuda M, Nagashima A, Haro A, Saitoh G. Aspergilloma mimicking a lung cancer. Int J Surg Case Rep 2013; 4:690-2. [PMID: 23792483 DOI: 10.1016/j.ijscr.2013.02.028] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2012] [Revised: 01/22/2013] [Accepted: 02/05/2013] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION Pulmonary aspergillosis occurs in the parenchymal cavities or ectatic airways. It rarely affects healthy people with an intact immune response. There have been few reports describing an aspergilloma mimicking a lung cancer. PRESENTATION OF CASE We experienced the case of an asymptomatic healthy 71-year-old female who was admitted with an abnormal lung shadow. Chest CT revealed an irregularly shaped solid lung nodule in the left upper lobe, which increased in size during the follow-up at a regional hospital. The pathology of the bronchial biopsy was negative for malignant cells, and the cultures were negative. Because a lung cancer was strongly suspected, video-assisted thoracic surgery was performed. Aspergillus was detected by a pathological study of the excised specimen, with no evidence of lung cancer. DISCUSSION It is difficult to make an accurate diagnosis of aspergilloma by imaging findings in healthy people with an intact immune response, and therefore a surgical resection allows both the pathological diagnosis and treatment to be performed concurrently. CONCLUSION An aspergilloma presenting a mass shadow on imaging may mimic a lung cancer in healthy people with intact immune response.
Collapse
Affiliation(s)
- Manabu Yasuda
- Department of Chest Surgery, Kitakyushu Municipal Medical Center, Japan.
| | | | | | | |
Collapse
|
23
|
Hirata H, Nakamura K, Kunitake N, Shioyama Y, Sasaki T, Ohga S, Nonoshita T, Yoshitake T, Asai K, Inoue K, Nagashima A, Ono M, Honda H. Association between EGFR-TKI resistance and efficacy of radiotherapy for brain metastases from EGFR-mutant lung adenocarcinoma. Anticancer Res 2013; 33:1649-1655. [PMID: 23564810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
AIM To clarify how patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma with acquired resistance to EGFR-tyrosine kinase inhibitors (TKIs) respond to radiotherapy (RT) for brain metastases. PATIENTS AND METHODS Forty-seven patients were divided into the following three groups: a TKI-naïve group with EGFR mutation (n=11), a TKI-resistant group with EGFR mutation (n=10), and an EGFR-wild-type group (n=26). Patients received stereotactic RT (n=23) or whole-brain RT (n=24). RESULTS The response rate for patients with TKI-resistant tumor at three months after RT tended to be lower (11%) than that of those who were TKI-naïve (82%, p=0.006) and for patients with wild-type EGFR (48%, p=0.10). On univariate analysis, central nervous system progression-free and overall survival were significantly shorter for patients with TKI-resistant tumors than for those who were TKI-naïve (p=0.018 and p=0.005, respectively). Multivariate analysis showed that TKI resistance was an independent predictor of poorer overall survival (p=0.011). CONCLUSION Acquired resistance to TKIs appears to be associated with low efficacy of brain RT.
Collapse
Affiliation(s)
- Hidenari Hirata
- Department of Radiology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Inoue T, Morita M, Tojo T, Nagashima A, Moritomo A, Imai K, Miyake H. Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema: part 2. Bioorg Med Chem 2013; 21:2478-94. [PMID: 23540955 DOI: 10.1016/j.bmc.2013.02.048] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2013] [Revised: 02/27/2013] [Accepted: 02/28/2013] [Indexed: 10/27/2022]
Abstract
Novel thiazole derivatives were synthesized and evaluated as vascular adhesion protein-1 (VAP-1) inhibitors. Although our previous compound 1 showed potent VAP-1 inhibitory activity, the activity differed between humans and rats. This issue was overcome by a hybrid design using human VAP-1 specific inhibitor 2, which was found by high-throughput screening (HTS), a docking study of a human VAP-1 homology model, and an analysis of sequence information for humans and rats. As a result, we identified compound 35c, which showed strong VAP-1 inhibitory activity (human IC(50) of 20 nM; rat IC(50) of 72 nM) and significant inhibitory effects in the ex vivo test.
Collapse
Affiliation(s)
- Takayuki Inoue
- Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan.
| | | | | | | | | | | | | |
Collapse
|
25
|
Inoue T, Morita M, Tojo T, Yoshihara K, Nagashima A, Moritomo A, Ohkubo M, Miyake H. Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema. Bioorg Med Chem 2013; 21:1219-33. [DOI: 10.1016/j.bmc.2012.12.025] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2012] [Revised: 12/19/2012] [Accepted: 12/20/2012] [Indexed: 11/25/2022]
|
26
|
Ichiki Y, Nagashima A, Yasuda M, Takenoyama M. Analysis of the surgical treatment for superior sulcus tumors. Surg Today 2012; 43:1419-24. [PMID: 23212702 DOI: 10.1007/s00595-012-0431-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2012] [Accepted: 10/01/2012] [Indexed: 11/30/2022]
Abstract
PURPOSE This study was undertaken to assess the mortality, complication, and major morbidity rates of surgical treatment for superior sulcus tumors (SSTs), and to estimate the significance of prognostic factors. METHODS We retrospectively reviewed the hospital records of 50 consecutive patients undergoing surgical treatment for SSTs between 1992 and 2007. The significance of risk factors for an adverse outcome was investigated. RESULTS Both the thirty-day and in-hospital mortality rates were 0 %. Complications developed in 18.0 % (9/50) of the patients. The overall 5-year survival was 32.7 %. Pathological T4 and N1 or more were the risk factors predicting an adverse outcome. Survival was not significantly influenced by the preoperative symptoms, the histological type, the invaded organ or the curability. CONCLUSION Surgical treatment for SSTs is associated with acceptable overall morbidity and mortality rates. However, special care must be taken for the patients with pathological T4 and N1 or higher tumors. Preoperative chemoradiotherapy followed by surgical treatment has become a logical strategy for SSTs. Preoperative chemoradiotherapy for SSTs may yield better results than surgery alone.
Collapse
Affiliation(s)
- Yoshinobu Ichiki
- Department of Chest Surgery, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-ku, Kitakyushu, 802-0077, Japan,
| | | | | | | |
Collapse
|
27
|
Hirata H, Nakamura K, Kunitake N, Shioyama Y, Sasaki T, Nonoshita T, Inoue K, Nagashima A, Ono M, Honda H. Acquired Resistance to EGFR Tyrosine Kinase Inhibitors is Associated With Low Efficacy of Radiation Therapy for Brain Metastases From EGFR-mutant Lung Adenocarcinoma. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
Ichiki Y, Nagashima A, Chikaishi Y, Yasuda M, Yamamoto I, Toyoshima S. Primary pulmonary Ewing's sarcoma: report of a case. Surg Today 2012; 42:812-5. [PMID: 22484982 DOI: 10.1007/s00595-012-0170-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2011] [Accepted: 07/25/2011] [Indexed: 11/28/2022]
Abstract
The Ewing's sarcoma family of tumors has been reported to originate in a variety of sites, most commonly in the extremities. We herein describe a rare case of primary pulmonary Ewing's sarcoma in a patient with a family history of sarcoma. The patient was a 42-year-old male, who presented with hemoptysis. Chest radiographs revealed a pulmonary mass in the right lower lobe. Clinical and radiological examinations (computed tomography and positron emission tomography) revealed that the lesion was a primary lesion. The lesion was resected by right lower lobectomy. The tumor was located in the pulmonary parenchyma, and there was no evidence of an extrapulmonary involvement by the tumor. Histologically, the tumor was composed of uniform cells with round nuclei and scant cytoplasm which were arranged in cohesive lobules with rare pseudorosette formation. Immunohistochemically, the tumor cells were positive for CD99, and negative for epithelial markers, neuroendocrine markers, myogenic markers and lymphoma markers. This diagnosis was further supported by the cytogenic and reverse transcriptase-polymerase chain reaction findings of EWS/FLI-1 fusion transcripts. This demonstrated the presence of a very rare primary pulmonary Ewing's sarcoma. The patient was treated with chemotherapy after the operation because Ewing's sarcoma is an aggressive neoplasm. The patient has had no recurrent disease for 6 months after the operation.
Collapse
Affiliation(s)
- Yoshinobu Ichiki
- Department of Chest Surgery and Pathology, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-ku, Kitakyushu, 802-0077, Japan.
| | | | | | | | | | | |
Collapse
|
29
|
Abstract
PURPOSE To assess the mortality, complications and major morbidity of pneumonectomy for non-small cell lung cancer (NSCLC) and to establish the importance of various prognostic factors. METHODS We reviewed retrospectively the hospital records of 71 consecutive patients who underwent pneumonectomy for NSCLC between 1992 and 2007 to evaluate the significance of risk factors for an adverse outcome. Patients were divided into two period groups according to the period when they were treated: early (1992-1999; n = 47) and late (2000-2007; n = 24). RESULTS Both the 30-day and the in-hospital mortality rates were 4.2 % (3/71). Complications developed in 31.3 % (22/71) and overall 5-year survival was 23.1 %. Pathological stage III or more, T3 or more, and N2 or more were risk factors of an adverse outcome. Survival was not significantly influenced by histological type, the side of surgery, or curability. The 5-year survival rates for the early and late periods were 19.6 and 32.9 %, respectively. There were more patients with clinical N2 or 3 disease in the early period than in the late period (66.0 vs. 33.3 %). CONCLUSIONS Pneumonectomy is associated with acceptable overall morbidity and mortality; however, patients with pathological stage III or more, T3 or more, and N2 or more disease require special consideration. Pneumonectomy should be performed only in selected patients.
Collapse
Affiliation(s)
- Yoshinobu Ichiki
- Department of Chest Surgery, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-ku, Kitakyushu, 802-0077, Japan.
| | | | | | | |
Collapse
|
30
|
Chikaishi Y, Nose N, Ichiki Y, Yasuda M, Nagashima A. [Chest wall reconstruction with rectus abdominis musculocutaneous flap for sternum osteomyelitis after radiation]. Kyobu Geka 2012; 65:209-212. [PMID: 22374596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
We report a case of reconstruction of radiation ulcer on the chest wall and sternum osteomyelitis using a rectus abdominis musculocutaneous flap. A case of 67-year-old woman, Halsted operation was performed for right breast cancer, 23 years ago. After 4 years, transcatheter arterial injection and radiation therapy was performed to treat recurrence of parasternal lymph nodes. Since then, she had been without recurrence of the tumor, but suffered from repeated scabbing of parasternal skin. In 2009, she suffered from pain, redness and purulent discharge of the wound, and diagnosed with sternum osteomyelitis. She was admitted to our hospital and underwent debridement of sternum, and the resection of surrounding skin. Sixteen days later, reconstruction using a rectus abdominis musculocutaneous flap was performed. Twenty months after the operation, she is well without any evidence of recurrence.
Collapse
Affiliation(s)
- Yasuhiro Chikaishi
- Department of Chest Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| | | | | | | | | |
Collapse
|
31
|
Yasuda M, Nagashima A, Ichiki Y, Takenoyama M, Moriyama K, Miyajima K. Operation for tracheal bronchus: 3-dimensional reconstruction imaging. Ann Thorac Surg 2011; 92:e127. [PMID: 22115270 DOI: 10.1016/j.athoracsur.2011.08.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2011] [Revised: 07/24/2011] [Accepted: 08/24/2011] [Indexed: 11/24/2022]
Affiliation(s)
- Manabu Yasuda
- Department of Chest Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
| | | | | | | | | | | |
Collapse
|
32
|
Yasuda M, Nagashima A, Chikaishi Y, Ichiki Y, Miyajima K. Utility of preoperative visualization for intrapulmonary sequestration in video-assisted thoracoscopic surgery. Int J Surg Case Rep 2011; 2:169-71. [PMID: 22096717 DOI: 10.1016/j.ijscr.2011.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2011] [Revised: 04/28/2011] [Accepted: 05/09/2011] [Indexed: 10/18/2022] Open
Abstract
We herein report the case of a 59-year-old male suffering from severe cough. The patient had previously experienced several episodes of pneumonia beginning in childhood. A three dimensional multidetector computed tomography (3D-MDCT) scan revealed pulmonary sequestration with a left gastric artery blood supply, and clearly revealed the other pulmonary vessels. The patient underwent video-assisted thoracoscopic surgery, in which the anomalous tissue was resected safely. Preoperative visualization of the vessels may be helpful for the safe treatment of a pulmonary sequestration, and the VATS approach is a suitable operation under corrective surgical planning.
Collapse
Affiliation(s)
- Manabu Yasuda
- Department of Chest Surgery, Kitakyushu Municipal Medical Center, 2-1-1 Basyaku, Kokurakita-ku, Kitakyushu 802-0077, Japan
| | | | | | | | | |
Collapse
|
33
|
Uramoto H, Nakanishi R, Nagashima A, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Sakata H, Nakanishi K, Yasumoto K. A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer. Anticancer Res 2010; 30:4695-4699. [PMID: 21115926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
BACKGROUND The benefits of adjuvant chemotherapy for completely resected non-small cell lung cancer (NSCLC) have been demonstrated using mainly cisplatin (CDDP)-based chemotherapeutic regimens. However, treatment-related deaths sometimes occur. Therefore, the development of a safer regimen is necessary. PATIENTS AND METHODS The patients were randomized to either carboplatin (CBDCA) area under the curve (AUC) 3 and paclitaxel (PTX) 90 mg/m(2) (PCb arm) or CBDCA (AUC3) plus gemcitabine (GEM) (1000 mg/m(2)) (GCb arm) every 2 weeks for 8 cycles after surgery. The primary endpoint was the compliance with the regimen, while the secondary endpoints were safety and toxicity. RESULTS A total of 75 patients were enrolled in a multi-institutional study. Twenty-one out of 39 patients (54%) in the PCb arm and 25 of 36 patients (69%) in the GCb arm completed 8 cycles, and 59% in the PCb arm and 81% in the GCb arm completed ≥6 cycles. The predominant toxicity was neutropenia. Non-hematological adverse effects were infrequent and no treatment-related death was registered. The estimated disease-free survival and overall survival at 2 years were 70.8% and 66.3% in the PCb and 91.4% and 79.1% in the GCb arm, respectively. CONCLUSION This adjuvant bi-weekly scheduled chemotherapy resulted in good compliance in both arms, and the regimen was feasible, with acceptable levels of toxicity in completely resected Japanese NSCLC patients. Therefore, these regimens represent a new treatment option suitable for outpatients with completely resected NSCLC.
Collapse
MESH Headings
- Adenocarcinoma/drug therapy
- Adenocarcinoma/pathology
- Adenocarcinoma/surgery
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Carboplatin/administration & dosage
- Carcinoma, Large Cell/drug therapy
- Carcinoma, Large Cell/pathology
- Carcinoma, Large Cell/surgery
- Carcinoma, Non-Small-Cell Lung/drug therapy
- Carcinoma, Non-Small-Cell Lung/pathology
- Carcinoma, Non-Small-Cell Lung/surgery
- Carcinoma, Squamous Cell/drug therapy
- Carcinoma, Squamous Cell/pathology
- Carcinoma, Squamous Cell/surgery
- Chemotherapy, Adjuvant
- Deoxycytidine/administration & dosage
- Deoxycytidine/analogs & derivatives
- Female
- Humans
- Lung Neoplasms/drug therapy
- Lung Neoplasms/pathology
- Lung Neoplasms/surgery
- Male
- Middle Aged
- Neoplasm Staging
- Paclitaxel/administration & dosage
- Prospective Studies
- Survival Rate
- Treatment Outcome
- Gemcitabine
Collapse
Affiliation(s)
- Hidetaka Uramoto
- Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Sugaya M, Uramoto H, Uchiyama A, Nagashima A, Nakanishi R, Sakata H, Nakanishi K, Hanagiri T, Yasumoto K. Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer. Anticancer Res 2010; 30:3039-3044. [PMID: 20683052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
BACKGROUND Adjuvant chemotherapy improves the prognosis of patients with non-small cell lung cancer (NSCLC) after a complete resection despite unacceptable toxicity and low compliance. METHODS A total of 67 patients were enrolled in a multi-institutional study. The patients received chemotherapy with carboplatin (CBDCA) area under the curve of 3 and paclitaxel (PTX) 90 mg/m(2) every 2 weeks for six cycles after surgery. RESULTS Fifty patients (74.6%) completed all cycles of therapy. The presence of grade 3 and 4 toxicities of neutropenia were 13.4, and 3.0%, respectively. Non-haematological adverse effects were infrequent and no treatment-related death was registered. The estimated disease-free survival and overall survival at 2 years were 89.0% and 88.8%, respectively. CONCLUSION A bi-weekly schedule of CBDCA and PTX as adjuvant chemotherapy showed an acceptable toxicity and favourable feasibility in Japanese NSCLC patients after complete tumor resection. Consequently, it is desirable to validate this regimen in a future randomized clinical trial.
Collapse
Affiliation(s)
- Masakazu Sugaya
- Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Nagasaka Y, Okada H, Suzuki J, Nagashima A. Absolute Measurements of the Thermal Conductivity of Aqueous NaCl Solutions at Pressures up to 40 MPa. ACTA ACUST UNITED AC 2010. [DOI: 10.1002/bbpc.19830871006] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
36
|
|
37
|
Ono K, Nagashima A, Yokoyama E, Nose N, Yasumoto K. [Long-term survival after surgical resection of bone metastasis from lung cancer]. Kyobu Geka 2010; 63:216-219. [PMID: 20214351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
BACKGROUND The prognosis of patients with bone metastasis from primary lung cancer is poor, and the effective treatment for bone metastasis had not been established. We report a case of more than 6 years survival after a surgical resection of rib metastasis. CASE A 56-years-old woman underwent right lower lobectomy and mediastinal lymph node dissection for lung cancer (well differentiated adenocarcinoma, pT1N0M0, stage IA) in another hospital in July 1995. In May 2003, the patient suffered right lateral chest pain and the chest computed tomography (CT) showed an osteolytic mass of right 5th rib. Percutaneous ultrasound-guided fine-needle aspiration cytology revealed adenocarcinoma and the tumor was diagnosed as bone metastasis from primary lung cancer. A chest wall resection for bone metastasis of right 5th rib was carried out and she underwent adjuvant chemotherapy. She is presently alive and well without recurrence more than 6 years after chest wall resection. CONCLUSION A resection of bone metastasis from lung cancer may offer the possibility of a long-term survival in selected patients.
Collapse
Affiliation(s)
- Kenji Ono
- Department of Chest Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| | | | | | | | | |
Collapse
|
38
|
Sugio K, Nagashima A, Nakanishi R, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Takenoyama M, Hanagiri T, Yasumoto K. Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7562 Background: Carboplatin plus paclitaxel and carboplatin plus gemcitabine chemotherapy have shown a good response and an improved survival against advanced NSCLC. This phase II trial assessed the feasibility, safety and efficacy of a bi-weekly schedule for adjuvant chemotherapy. Methods: Patients with completely resected stage IB-IIIB NSCLC were randomized to either carboplatin (AUC3) plus paclitaxel (90mg/m2) (arm A) or carboplatin (AUC3) plus gemcitabine (1000 mg/m2) (arm B), q2w for 8 cycles within 8 weeks after surgery. The main inclusion criteria were no prior chemotherapy or radiotherapy, ECOG PS 0–1, an age of less than 80 years, and an adequate organ function. The primary endpoint was compliance, and secondary endpoints were the disease free survival (DFS) and toxicity. The patients were stratified by gender, histology (adenoca vs. non-adenoca) and disease stage. Results: Between 07/2005 and 06/2007, 76 patients were randomized and 75 were eligible (including 48 males, 27 females; median age 66 years) for intent-to-treat analysis (39 in arm A, 36 in arm B). The histologic types included adenocarcinoma (n=51), squamous cell carcinoma (n=18), large cell carcinoma (n=5), and adenosquamous cell carcinoma (n=1). The pathological stages were IB/IIA/IIB/IIIA/IIIB: 22/10/13/29/1. Twenty-one of 39 pts (54%) in arm A and 25 of 36 pts (69%) in arm B completed 8 cycles, and 59% in arm A and 81% in arm B completed ≥6 cycles. Grade 3/4 hematologic toxicities (%) in arms A/B were respectively; neutropenia 36/53, anemia 0/17, thrombocytopenia 3/0, nausea 3/3. No treatment related deaths were observed. Up to 12/2008, 11 of 39 pts in arm A and 13 of 36 pts in arm B had recurrent disease, but no significant difference was observed. Conclusions: This adjuvant bi- weekly scheduled chemotherapy in both arms resulted in a good compliance and feasible with acceptable levels of toxicity in completely resected NSCLC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Sugio
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - A. Nagashima
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - R. Nakanishi
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - A. Uchiyama
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - M. Inoue
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - T. Osaki
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - T. Yoshimatsu
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - M. Takenoyama
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - T. Hanagiri
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - K. Yasumoto
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| |
Collapse
|
39
|
Nagata Y, Hanagiri T, Mizukami M, Kuroda K, Shigematsu Y, Baba T, Ichiki Y, Yasuda M, So T, Takenoyama M, Sugio K, Nagashima A, Yasumoto K. Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan. Lung Cancer 2008; 65:91-7. [PMID: 19054590 DOI: 10.1016/j.lungcan.2008.10.012] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2008] [Revised: 09/09/2008] [Accepted: 10/05/2008] [Indexed: 11/25/2022]
Abstract
BACKGROUND The role of the HLA phenotype in cancer prognosis has been frequently discussed. We previously reported the correlation between HLA alleles and the postoperative prognosis of 204 patients with non-small cell lung cancer (NSCLC). The present study was based on 695 patients with NSCLC to confirm these correlations. METHODS We evaluated the medical records of 695 NSCLC patients who underwent surgical resection. The serological typing of HLA class I was performed using a microcytotoxicity test of lymphocytes or PCR-sequence-specific oligonucleotides (PCR-SSO), and the correlation between the HLA alleles and the clinicopathological features was analyzed. The survival curves were calculated, and then a comparison of the survival curves was carried out. RESULTS The HLA-A2 positive(A2(+)) group at stage I showed a more unfavorable prognosis than HLA-A2(-) group in overall survival. At stage II+III, the HLA-A24(+) group had a poorer prognosis than the HLA-A24(-) group, and the HLA-B52(+) group showed unfavorable prognosis. Multivariate analysis demonstrated that HLA-A2 at stage I and HLA-A24 at stage II+III were the independent factors that affected the survival period. CONCLUSIONS The expression of HLA-A2 was considered as one of the unfavorable prognostic factors in the NSCLC patients at stage I. HLA-A24(+) group showed a significant unfavorable prognosis at stage II+III. These results suggested that HLA-A2 and HLA-A24 could be the prognostic factors in patients with NSCLC according to the state of advancement of the disease.
Collapse
Affiliation(s)
- Yoshika Nagata
- Second Department of Surgery, University of Occupational and Environmental Health, School of Medicine, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu-city, Fukuoka 807-8555, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Ono K, Nagashima A, Inaba G, Iwanami T, Yasumoto K. [Postoperative recurrence of spontaneous pneumothorax]. Kyobu Geka 2008; 61:1011-1014. [PMID: 19048897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Few reports on recurrence after thoracoscopic bullectomy for spontaneous pneumothorax specify the follow-up period and follow-up ratio. Because of the variation in follow-up periods, many reported recurrence rates were not comparable. Some reports compared simple recurrence rate (number of recurrent cases/number of operated cases) of different groups with different follow-up periods. In this study, we employ the Kaplan-Meier method along with a set of optimal follow-up periods and ratios in order to determine a more reliable recurrence rate. Consecutive 68 patients (74 surgical procedures) underwent thoracoscopic bullectomy for spontaneous pneumothorax at our institution between November 2000 and December 2005. A follow-up survey was conducted by phone to determine the rate of recurrent pneumothorax. The follow-up ratio and the mean follow-up period were 92.6% and 1,316 +/- 481 days, respectively. Postoperative recurrence was confirmed for 4 patients. The interval up to recurrence was 144, 345, 476 and 616 days after the bullectomy, respectively. All cases of recurrent pneumothorax occurred within 2 years following the bullectomy. The 1-year, 2-year and 3-year cumulative recurrence rate was 3.0%, 6.3% and 6.3%, respectively. In light of these findings, we feel that comparison analysis of pneumothorax recurrence rates should be evaluated using the Kaplan-Meier method, furthermore, our data suggests that a follow-up period of 2 or more years is advisable.
Collapse
Affiliation(s)
- K Ono
- Department of Chest Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| | | | | | | | | |
Collapse
|
41
|
Kikugawa Y, Nagashima A, Sakamoto T. Intramolecular Benzylic Cyclization with Nitrenium Ions Generated from N-Acylaminophthalimides Using Phenyliodine(III) Bis(trifluoroacetate): Formation of Phenyl Substituted Lactams. HETEROCYCLES 2007. [DOI: 10.3987/com-07-s(w)4] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
42
|
Yoshino I, Ichinose Y, Nagashima A, Takeo S, Motohiro A, Yano T, Yokoyama H, Ueda H, Sugio K, Ishida T, Yasumoto K, Maehara Y. Clinical characterization of node-negative lung adenocarcinoma: results of a prospective investigation. J Thorac Oncol 2006; 1:825-31. [PMID: 17409966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
OBJECTIVES In clinical stage IA lung adenocarcinoma, the clinical features of a truly node-negative population were prospectively investigated by means of a prospective investigational study. METHODS The clinical data and radiographic features of high-resolution computed tomography (HR-CT) were registered before operation in 169 clinical stage IA lung cancer patients who were scheduled to undergo a standard lobectomy and systemic mediastinal node dissection. The nodal metastasis was pathologically defined and the clinical factors associated with the presence of the nodal metastasis were evaluated. RESULTS In 114 assessable cases with adenocarcinomas, 15 (13.1%) were node-positive. The serum carcinoembryonic antigen (CEA), retraction sign, and intratumoral air-bronchogram on HR-CT were suggested to be predictive factors for lymph node metastasis, with hazard ratios of 12.44 (p = 0.0003), 6.53 (p = 0.0533), and 0.17 (p = 0.0073), respectively. In combination with the radiologic features and serum CEA, cases with elevated serum CEA or presence of retraction sign included 15.6% of node metastasis-positive, whereas all cases with normal CEA and absence of retraction sign showed no nodal metastasis. Cases with elevated serum CEA or absence of intratumoral air-bronchogram included 24.5% of node metastasis, whereas cases with normal CEA and presence of air-bronchogram showed 4.6% of node metastasis. The tumor size and the proportion of ground-glass attenuation were not associated with the incidence of nodal metastasis. CONCLUSIONS The serum CEA and HR-CT features thus allowed us to identify node-negative lung adenocarcinomas measuring 3 cm or less in size.
Collapse
Affiliation(s)
- Ichiro Yoshino
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Yoshino I, Ichinose Y, Nagashima A, Takeo S, Motohiro A, Yano T, Yokoyama H, Ueda H, Sugio K, Ishida T, Yasumoto K, Maehara Y. Clinical Characterization of Node-Negative Lung Adenocarcinoma: Results of a Prospective Investigation. J Thorac Oncol 2006. [DOI: 10.1016/s1556-0864(15)30412-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
44
|
Hazama S, Nagashima A, Kondo H, Shimizu R, Araki A, Yoshino S, Okayama N, Hinoda Y, Oka M. A genetic UGT1A1 polymorphism oriented phase I study of irinotecan (CPT-11) and doxifluridine (5’-DFUR: An intermediate form of capecitabine for metastatic colorectal cancer (MCRC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3602 Background: 5-Fluorouracil plus CPT-11 is one of the standard 1st-line therapies in patients (pts) with metastatic colorectal cancer (MCRC). Although it has been reported that individuals carrying the (TA) 7 allele in the TATAA promoter of UGT1A1 increased risk of severe toxic event occurrence after CPT-11 administration, there is no report about phase I study based on the polymorphism of UGT1A1. Here we report the results from a genetic UGT1A1 polymorphism oriented phase I study of CPT-11 and 5’-DFUR to determine the maximum tolerated dose (MTD) and the recommend doses (RD) for each UGT1A1 genotypes. Methods: Eligibility criteria were as follows; histologically proven CRC with unresectable metastatic lesions, PS 0–2, age<76, adequate organ functions, and written informed consent. CPT-11 was infused (level 1, 2, 3 and 4: 70, 100, 120, 150 mg/m2, respectively) biweekly and 5’-DFUR was administered orally (800 mg/body, <1.39 m2; 600 mg/body) on 5 consecutive days with 2 days’ rest for more than 12 weeks. DLT were determined as grade 3 hematological and non-hematological toxicities. Genotypes were determined by analyzing the sequence of TATA box of UGT1A1 of genomic DNA from pts. Results: Eighteen pts with wild 6/6 allele and 9 pts with mutated 6/7 allele were registered. In pts with 6/6 allele, MTD was not observed up to level 4 (150 mg/m2). In pts with mutated 6/7 allele, on the other hand, MTD was observed at level 2 (100 mg/m2). We recommend doses of 70 mg/m2 of CPT-11 for pts with mutated 6/7 allele and 150 mg/m2 of CPT-11 for pts with wild 6/6 allele, respectively. Conclusions: The recommended phases II/III starting doses of biweekly CPT-11 administration are 150 mg/m2 for pts with wild 6/6 allele and 70 mg/m2 of CPT-11 for pts with mutated 6/7 allele, and 5’ -DFUR 800 mg/body on every 5 days per week. This combination therapy may be administered safely for all pts according to the TATAA promoter polymorphism of UGT1A1. The gene polymorphism should be taken into consideration to provide more precise information to guess the individual toxicities. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | - H. Kondo
- Yamaguchi University, Ube, Japan
| | | | - A. Araki
- Yamaguchi University, Ube, Japan
| | | | | | | | - M. Oka
- Yamaguchi University, Ube, Japan
| |
Collapse
|
45
|
Yoshino I, Ichinose Y, Nagashima A, Takeo S, Motohiro A, Yano T, Ishida T, Yamazaki K, Sugio K, Yasumoto K, Maehara Y. Clinical characterization of node-negative non-small cell lung cancer: Results of a prospective investigation. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7218 Background: 20 to 30% of clinical stage IA non-small cell lung cancer cases were revealed to be node-positive by pathologic examination of resected specimens. In this prospective study, the clinical features of a truly node-negative population were prospectively investigated to search for candidates of a lesser resection or of a stereotactic radiotherapy. Methods: The clinical data and radiographic features of high-resolution computed tomography (HR-CT) were registered before operation in 169 clinical stage IA lung cancer patients, who were scheduled to undergo a standard lobectomy and systemic mediastinal node dissection. The nodal metastasis was pathologically defined, while the clinical factors associated with the presence of the nodal metastasis were evaluated. Results: In 130 evaluable cases, 16 of 114 adenocarcinoma and 3 of 16 other NSCLC were node-positive. Among all parameters, positivity of the serum carcinoembryonic antigen (CEA) was the only factor significantly associated with nodal metastasis (p = 0.0074). When we focused on adenocarcinomas, the serum CEA, retraction sign and intratumoral air-space on HR-CT were suggested to be predictive factors for lymph node metastasis with hazard ratios of 12.44 (p = 0.0003), 6.53 (p = 0.0533) and 0.17 (0.0073), respectively. In combination with the radiologic features of HR-CT imaging, none of 18 CEA-negative/retraction-negative cases and 3 of 65 CEA-negative/air-space positive cases showed nodal metastasis, in which the incidence of nodal metastasis was significantly lower than the counterparts with respective p-values of 0.0015 and 0.037. The tumor size and the proportion of ground glass attenuation were not associated with the incidence of nodal metastasis. Conclusions: The serum CEA and HR-CT features thus allowed us to identify node-negative lung adenocarcinomas. In clinical stage IA adenocarcinoma cases, a standard operation should be considered when positive serum CEA and/or retraction sign on HRCT is noticed. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- I. Yoshino
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - Y. Ichinose
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - A. Nagashima
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - S. Takeo
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - A. Motohiro
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - T. Yano
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - T. Ishida
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - K. Yamazaki
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - K. Sugio
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - K. Yasumoto
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - Y. Maehara
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| |
Collapse
|
46
|
Sugaya M, Sugio K, Nagashima A, Nakanishi R, Sakata H, Nakanishi K, Ono K, Uramoto H, Hanagiri T, Yasumoto K. Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7258] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Sugaya
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - K. Sugio
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - A. Nagashima
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - R. Nakanishi
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - H. Sakata
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - K. Nakanishi
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - K. Ono
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - H. Uramoto
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - T. Hanagiri
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - K. Yasumoto
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| |
Collapse
|
47
|
Nagashima A, Tanaka E, Inomata S, Honda K, Misawa S. A study of the in vitro interaction between lidocaine and premedications using human liver microsomes*. J Clin Pharm Ther 2005; 30:185-8. [PMID: 15811173 DOI: 10.1111/j.1365-2710.2004.00617.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE To investigate potential interactions between lidocaine (lignocaine) metabolism and premedication drugs, i.e. psychotropic and antianxiety agents (diazepam, midazolam), hypnotics (pentobarbital, thiamylal), depolarizing neuromuscular blocking agents (vecuronium, pancuronium and suxamethonium), an antihypertensive agent (clonidine) and an H2-receptor blocking agent (cimetidine) using human liver microsomes in vitro. METHODS The interaction effects between lidocaine and premedication were examined using human liver microsomal preparations and monitored for enzyme activity. The lidocaine and its main metabolite (monoethylglycinexylide) were measured by HPLC/UV. RESULTS Lidocaine metabolism was non-competitively inhibited by midazolam (Ki = 77.6 microM). Thiamylal was a competitive inhibitor of lidocaine metabolism (Ki = 885 microM). Cimethidine, pancuronium and vecuronium weakly inhibited lidocaine metabolism in a concentration-depend manner over the therapeutic range in human liver microsomes. On the contrary, suxamethonium, pentobarbital and clonidine did not inhibit lidocaine metabolism over the therapeutic range in human liver microsomes. CONCLUSION These results show that the interactions between lidocaine and midazolam and thiamylal are of potential toxicological and clinical significance.
Collapse
Affiliation(s)
- A Nagashima
- Institute of Community Medicine, University of Tsukuba, Ibaraki-ken, Japan
| | | | | | | | | |
Collapse
|
48
|
Hazama S, Matoba K, Nagashima A, Matsuoka K, Oka M. A phase I study of irinotecan and 5'-DFUR in patients with metastatic colorectal cancer: With consideration of gene polymorphism. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Hazama
- Yamaguchi University School of Medicine, Ube, Japan
| | - K. Matoba
- Yamaguchi University School of Medicine, Ube, Japan
| | - A. Nagashima
- Yamaguchi University School of Medicine, Ube, Japan
| | - K. Matsuoka
- Yamaguchi University School of Medicine, Ube, Japan
| | - M. Oka
- Yamaguchi University School of Medicine, Ube, Japan
| |
Collapse
|
49
|
Abstract
Lung cancer metastasis to the liver indicates a poor prognosis, and the majority of patients with metastatic disease to the liver are not indicated for surgery because of the number or distribution of metastases or the presence of extrahepatic disease. We herein describe a case of long-term survival after a surgical resection of liver metastases from lung cancer. Six months after surgery for Stage IB primary lung adenocarcinoma, a 71-year-old male was found to have a metastatic tumor in his liver. A hepatic resection for the metastatic tumor and another small metastatic foci found intraoperatively was carried out, and the tumors were pathologically diagnosed as liver metastases from lung cancer. The patient is presently alive and well without recurrence, as of 5 years and 2 months after the liver resection. This is the first report of the successful surgical treatment of liver metastasis from lung cancer.
Collapse
Affiliation(s)
- Akira Nagashima
- Department of Chest Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| | | | | | | | | |
Collapse
|
50
|
Osaki T, Nagashima A, Yoshimatsu T, Tashima Y, Yasumoto K. Survival and characteristics of lymph node involvement in patients with N1 non-small cell lung cancer. Lung Cancer 2004; 43:151-7. [PMID: 14739035 DOI: 10.1016/j.lungcan.2003.08.020] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
N1 non-small cell lung cancer (NSCLC) encompasses a heterogeneous subgroup with differential lymph node involvement. Among 738 patients with NSCLC who underwent surgical resection, including 579 patients (78.5%) with systematic hilar and mediastinal lymph nodal dissection, from 1992 to 2001, 82 patients were pathologically defined as having N1 disease. We retrospectively analyzed the factors influencing survival, including the characteristics of lymph node involvement; the location of involved stations, the number of involved stations, the number of involved nodes, and the status of nodal involvement (microscopic N1, nodal involvement first defined by postoperative histological examination; or macroscopic N1, nodal involvement obviously recognized by preoperative examinations or surgical explorations). The overall 5-year survival rate of the 82 patients with N1 disease was 50.9%. No significant differences in the overall survival were found with regard to gender, age, histologic type, type of resection, or adjuvant therapies. Pathologic T status significantly influenced the overall survival (T1 versus T2 disease, P=0.008). According to the characteristics of lymph node involvement, the prognosis of patients with multiple-node N1 involvement was significantly poorer than that of those with single-node N1 involvement (5-year survival: 29.6% versus 61.5%, p=0.003). The prognosis of patients with macroscopic N1 disease was significantly poorer than that of those with microscopic N1 disease (5-year survival: 43.0% versus 65.0%, P=0.046). By comparison with the survival of patients who underwent surgical resection during the same period for pathologic N0 (pN0) and pathologic N2 (pN2) diseases, no survival differences were observed between microscopic N1/single-node N1 and pN0, or between multiple-node N1 and pN2 diseases. In patients with pathologic N1 disease, microscopic N1 and single-node N1 diseases may be an early stage, whereas multiple-node N1 disease behaves like an advanced stage.
Collapse
Affiliation(s)
- Toshihiro Osaki
- Department of Chest Surgery, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-ku, Kitakyushu 802-0077, Japan.
| | | | | | | | | |
Collapse
|